

## **Dr. Alan Snow to Present at the XIV International Symposium on Amyloidosis and the Cavendish Global Health Impact Forum**

KIRKLAND, Wash., April 25, 2014- ProteoTech Inc. (ProteoTech) today announced that Dr. Alan Snow, ProteoTech's President & Chief Scientific Officer will present an oral presentation at the XIV International Symposium on Amyloidosis and the Cavendish Global Health Impact Forum.

Dr. Snow's presentation at the XIV International Symposium on Amyloidosis (Indianapolis, IN) will take place on Thursday May 1, 2014 and is entitled "The Small Molecule Systebryl™ (PTI-110) Causes Potent Disaggregation/Reduction of AL, TTR and AA Amyloidosis". The International Symposium on Amyloidosis is held every 2 years and brings together the top amyloid researchers in the world. Dr. Snow will discuss ProteoTech's lead compound, Systebryl™ (PTI-110) and its ability to disaggregate and reduce amyloid fibril deposits of the AL (immunoglobulin light chain), TTR (transthyretin) and AA (inflammation-associated amyloidosis; AA amyloid) amyloid types.

In addition, ProteoTech has recently been accepted to be a Cavendish Innovation Partner and Dr. Alan Snow has been invited to give a talk at the Cavendish Global Family Office and Foundation Impact Forum Health and the Life Sciences to be held at the United Nations Headquarters in New York on May 5-7, 2014. The Cavendish forum brings together leading family offices and their foundations seeking well-conceived impact investment, grant-giving and philanthropy opportunities within health and the life sciences. Participation at the invitation only event includes private sector companies, some of the best scientific minds, accomplished healthcare delivery professionals, philanthropic organizations, and health policy experts engaged in transforming medical outcomes on a regional, national and global basis.

ProteoTech is a private, therapeutic development Company that utilizes its amyloid expertise to discover and develop new drugs for treating misfolding protein disorders and amyloid diseases. ProteoTech's lead small molecule compound, Systebryl (PTI-110) will soon be entering Phase I/II proof-of-concept studies in AL (immunoglobulin light chain) amyloidosis (an orphan disease). Other drugs in the pipeline, include a small molecule drug inhibitor for TTR (transthyretin) amyloidosis, a small molecule drug inhibitor of alpha-synuclein accumulation (for Parkinson's disease and other synucleinopathies), and a small molecule drug that works both on the beta-amyloid protein and tau protein of Alzheimer's disease. For further information, please contact Dr. Roger Flugel, Chief Business Officer ([flugel@proteotech.com](mailto:flugel@proteotech.com)) or Dr. Alan Snow, President & CSO ([snow@proteotech.com](mailto:snow@proteotech.com))